Alarming rise in child deaths from antimicrobial resistance
New research reveals over 3 million children died globally from AMR-related infections in 2022, with particular concerns about increasing use of critical antibiotic classes.
This author has yet to write their bio.
New research reveals over 3 million children died globally from AMR-related infections in 2022, with particular concerns about increasing use of critical antibiotic classes.
New research identifies interleukin-6 as a superior diagnostic biomarker for sepsis in high-risk populations including neonates, children, and pregnant women.
Safety concerns prompt Pfizer to terminate development of once-daily oral GLP-1 receptor agonist for weight management, despite promising pharmacokinetic data from recent dose-optimisation studies.
Basel’s equity-free pharma-focused accelerator programme returns to bridge the gap between healthtech innovations and pharmaceutical R&D needs.
Bruker Corporation has announced significant expansions to its infectious disease testing solutions at the ESCMID Global conference in Vienna, including a broader assay menu for its BeGenius® molecular diagnostics system and improvements to its microbial identification platforms.
Beckman Coulter Life Sciences has launched a ground-breaking Next-Generation Basophil Activation Test (BAT) that could transform food allergy research by eliminating the need for potentially dangerous allergen exposure.
Bio-Rad Laboratories has achieved a significant regulatory milestone with EU Quality Management Systems certification under the In Vitro Diagnostic Regulation (IVDR), enabling CE marking for 40 infectious disease molecular quality control products from their Exact Diagnostics brand.
Revvity, Inc. has significantly expanded its collaboration with Genomics England to provide comprehensive genomic screening services for newborns in England. The new agreement builds upon an existing partnership by adding DNA sequencing services to Revvity’s current DNA extraction capabilities.
Cambridge-based 4basebio has received Good Manufacturing Practice certification from the UK’s Medicines and Healthcare products Regulatory Agency, enabling the company to supply GMP-grade synthetic DNA for clinical applications in cell and gene therapy development.
The Cystic Fibrosis Foundation has committed up to US$2.3 million (about £1.7 million) in equity investment to Owlstone Medical for the development of a breath test to detect Pseudomonas aeruginosa (PA) infections in people with cystic fibrosis (CF). The Cambridge-based company announced the investment on March 25, 2025, marking a significant step forward in respiratory […]
February | March 2025
The leading international magazine for Clinical laboratory Equipment for everyone in the Vitro diagnostics
Beukenlaan 137
5616 VD Eindhoven
The Netherlands
+31 85064 55 82
info@clinlabint.com
PanGlobal Media is not responsible for any error or omission that might occur in the electronic display of product or company data.
This site uses cookies. By continuing to browse the site, you are agreeing to our use of cookies.
Accept settingsHide notification onlyCookie settingsWe may ask you to place cookies on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience and to customise your relationship with our website.
Click on the different sections for more information. You can also change some of your preferences. Please note that blocking some types of cookies may affect your experience on our websites and the services we can provide.
These cookies are strictly necessary to provide you with services available through our website and to use some of its features.
Because these cookies are strictly necessary to provide the website, refusing them will affect the functioning of our site. You can always block or delete cookies by changing your browser settings and block all cookies on this website forcibly. But this will always ask you to accept/refuse cookies when you visit our site again.
We fully respect if you want to refuse cookies, but to avoid asking you each time again to kindly allow us to store a cookie for that purpose. You are always free to unsubscribe or other cookies to get a better experience. If you refuse cookies, we will delete all cookies set in our domain.
We provide you with a list of cookies stored on your computer in our domain, so that you can check what we have stored. For security reasons, we cannot display or modify cookies from other domains. You can check these in your browser's security settings.
.These cookies collect information that is used in aggregate form to help us understand how our website is used or how effective our marketing campaigns are, or to help us customise our website and application for you to improve your experience.
If you do not want us to track your visit to our site, you can disable this in your browser here:
.
We also use various external services such as Google Webfonts, Google Maps and external video providers. Since these providers may collect personal data such as your IP address, you can block them here. Please note that this may significantly reduce the functionality and appearance of our site. Changes will only be effective once you reload the page
Google Webfont Settings:
Google Maps Settings:
Google reCaptcha settings:
Vimeo and Youtube videos embedding:
.U kunt meer lezen over onze cookies en privacy-instellingen op onze Privacybeleid-pagina.
Privacy policy